… RNAtherapy Find out how RNAtherapy works, how it differs from … underlying cause of the disease. Watch: How do ProQR's RNA therapies work? A short introduction to RNA therapies Why focus on RNA therapies? Why focus on RNA therapies? RNA therapies can …
… Board with Leaders in Inherited Retinal Disease and RNATherapy LEIDEN, Netherlands & CAMBRIDGE, Mass., July 21, 2020 … to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today …
… diagnosed with a rare disease, he started ProQR to develop RNA therapies for rare diseases. Before founding ProQR, Mr. … of Amylon Therapeutics. He served as professor of gene therapy at the University of Leiden, received his Master’s …
… biotech company advancing our proprietary Axiomer RNA-editing platform technology. We are ProQR We are ProQR We … company dedicated to changing lives by developing RNA therapies for severe rare and common diseases. We focus … and Cambridge, Massachusetts, USA. Learn more about RNAtherapy and our Axiomer technology . We are on a mission We …
… of what we do. Our passion lies in discovering the latest RNA technologies and translating them to life-changing … where our scientists discover and test our novel RNA therapies. Our passion lies in discovering the latest RNA … platform technology. Interne link View this technology RNAtherapy Our antisense oligonucleotides are designed to …
… Trial enrollment continuing for three clinical stage RNA therapies in development for inherited retinal diseases, … (SAB) with leaders in inherited retinal disease and RNAtherapy. The SAB members are: James Shannon, MD, Chair of the …
… to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today … (SAB) with leaders in inherited retinal disease and RNAtherapy. In February, ProQR announced its participation in …
… to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today … 1b/2 trial results of the intravitreal sepofarsen RNAtherapy in LCA10 (encore presentations) Full-field stimulus …
… to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today hosted a … trial and is a first-in-class investigational RNAtherapy designed to address the underlying cause of Leber …
… on track to be reported in H2 2020; Three clinical stage RNA therapies in development for inherited retinal diseases, … trial and is a first-in-class investigational RNAtherapy designed to address the underlying cause of Leber …